---
title: Update Breast Cancer 2024 Part 1 - Expert Opinion on Advanced Breast Cancer
date: '2024-06-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38884028/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240617181223&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Clinical evidence is interpreted based on clinical studies and personal
  experience which can lead to different interpretations of data. This makes the opinions
  issued by panels of experts such as the Advanced Breast Cancer Panel which convened
  in November 2023 for the seventh time (ABC7) particularly important. At the conference,
  current issues around advanced breast cancer were evaluated by an international
  team of experts. In 2023 the data on CDK4/6 inhibitors was so extensive that the
  ...
disable_comments: true
---
Clinical evidence is interpreted based on clinical studies and personal experience which can lead to different interpretations of data. This makes the opinions issued by panels of experts such as the Advanced Breast Cancer Panel which convened in November 2023 for the seventh time (ABC7) particularly important. At the conference, current issues around advanced breast cancer were evaluated by an international team of experts. In 2023 the data on CDK4/6 inhibitors was so extensive that the ...